BioCentury This Week Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and new leadership at FDA shuffled the regulatory deck. On the latest BioCentury This Week podcast, BioCentury’s analysts make their picks for the biggest biopharma readouts, deals and regulatory and policy moves of 2025 and what they are forecasting for the year ahead.
The analysts also recap biotech highlights of the past two weeks, including the $4.8 billion takeout of Amicus Therapeutics by BioMarin Pharmaceutical.
View full story: https://www.biocentury.com/article/657933
#BiotechOutlook2026 #BiopharmaTrends #BiotechMA #FDALeadership #ChinaBiotech
00:00 - Introduction
02:31 - BioMarin's $4.8B Amicus Deal
06:07 - Year-end Biotech Highlights
16:37 - Analyst Picks and Predictions
30:01 - Policy and Regulatory Landscape
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.